EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3

Megumi Sato, Junnosuke Miura, Hikaru Oyatsu, Yuka Yoshida, Shota Mochizuki iD, Michio Otsuki, Tomoko Nakagami

Journal of Diabetes Investigation · 2026-05 · 17 (5) · 892-896

DOI: 10.1111/jdi.70260 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 17.03.2026. Verfasst von Megumi Sato und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Jap…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Glutamate Decarboxylase, Autoantibodies. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 61‐year‐old man visited our hospital with a sudden onset of polydipsia and polyuria occurring 5 days prior, accompanied by a 5‐kg weight loss. A month prior, his glycated hemoglobin level was 6.2%. Precisely 8 days before the first visit, he had a fever, and hyperglycemic symptoms began shortly thereafter. At the first visit, he had a blood glucose level of 465 mg/dL, a glycated hemoglobin level of 7.7%, and ketosis. He was diagnosed with fulminant type 1 diabetes mellitus. The antiglutamic acid decarboxylase (GAD) antibodies were >2000 IU/mL, without other pancreatic islet‐related autoantibodies. The human leukocyte antigen haplotype was DRB1*09:01‐DQB1*03:03 and DRB1*13:02‐DQB1*06:04 . Intensive insulin therapy was initiated, and the patient was admitted for monitoring the blood glucose profile. The anti‐GAD antibody turned negative approximately 7 months later. Some infections may have triggered rapid pancreatic islet destruction in an autoimmunity‐induced impaired glucose tolerance state.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Glutamate DecarboxylaseAutoantibodiesHumansMaleMiddle AgedDisease Progression

Stichwörter der Autor:innen

HLA haplotypeanti‐glutamic acid decarboxylase antibodyfulminant type 1 diabetes mellitus

Substanzen

Glutamate DecarboxylaseAutoantibodies

Autor:innen und Institutionen

  • Division of Diabetology and Metabolism, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Division of Endocrinology, Department of Internal Medicine, Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Tokyo, Japan.

ORCID-Profile: Shota Mochizuki

Zitieren

APA

Sato, M., Miura, J., Oyatsu, H., Yoshida, Y., Mochizuki, S., Otsuki, M., & Nakagami, T. (2026). Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3. Journal of Diabetes Investigation, 17(5), 892-896. https://doi.org/10.1111/jdi.70260

Vancouver

Sato M, Miura J, Oyatsu H, Yoshida Y, Mochizuki S, Otsuki M, et al. Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3. Journal of Diabetes Investigation. 2026;17(5):892-896. doi:10.1111/jdi.70260

BibTeX
@article{Sato2026,
  author = {Sato, Megumi and Miura, Junnosuke and Oyatsu, Hikaru and Yoshida, Yuka and Mochizuki, Shota and Otsuki, Michio and Nakagami, Tomoko},
  title = {Fulminant type 1 diabetes with high‐titer anti‐glutamic acid decarboxylase antibodies: Likely rapid progression from stage 2 to 3},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  volume = {17},
  number = {5},
  pages = {892--896},
  doi = {10.1111/jdi.70260}
}
Kostenlos starten →